Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03912532 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
A Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT03912532 is a Phase 2 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 171 participants, below the 263-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03912532, a Phase 2 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL NGM282
Study Locations (20)
California
- NGM Clinical Study Site - Fresno
- NGM Clinical Study Site - La Jolla
- NGM Clinical Study Site - Los Angeles
- NGM Clinical Study Site - Los Angeles
- NGM Clinical Study Site - Poway
- NGM Clinical Study Site - Rialto
Florida
- NGM Clinical Study Site - Boca Raton
- NGM Clinical Study Site - Lakewood Rch
- NGM Clinical Study Site - Port Orange
- NGM Clinical Study Site - Sarasota
- NGM Clinical Study Site - The Villages
Arizona
- NGM Clinical Study Site - Chandler
- NGM Clinical Study Site 814 - Tucson
- NGM Clinical Study Site 816 - Tucson
Arkansas
- NGM Clinical Study Site - North Little Rock
Illinois
- NGM Clinical Study Site - Chicago
Louisiana
- NGM Clinical Study Site - Baton Rouge
Maryland
- NGM Clinical Study Site - Baltimore
Michigan
- NGM Clinical Study Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03912532
The ClinicalTrials.gov registry entry for NCT03912532 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (35% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03912532 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03912532 about?
NCT03912532 is a clinical study titled "Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)". This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
What is the current status of trial NCT03912532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2019-05-16. Estimated completion is 2021-03-29.
What conditions does trial NCT03912532 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT03912532?
The interventions under investigation include: Placebo (OTHER), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03912532?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03912532 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
ACTIVE NOT RECRUITING · Phase 2
-
Statins for the Treatment of NASH
ACTIVE NOT RECRUITING · Phase 2
-
Tocotrienol Against the Progression of End Stage Liver Disease
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
COMPLETED · Phase 2
-
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.